Liquidia (LQDA) has rebounded with YUTREPIA's FDA approval and $51.7M in Q3 net product sales, but valuation remains fragile. Current sales and script numbers are influenced by channel inventory, GTN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results